1. 2005
2. Cyhoeddwyd

   Drugs for exceptionally rare diseases: do they deserve special status for funding?

   Hughes, D., Tunnage, B. & Yeo, S. T., 1 Tach 2005, Yn: QJM - An International Journal of Medicine. 98, 11, t. 829-836

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Incorporating measures of compliance and persistence in pharmacoeconomic evaluations

   Hughes, D., Hughes, D. A. & Cowell, W., 1 Tach 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

4. Cyhoeddwyd

   Public funding of drugs for orphan diseases

   Hughes, D. & Hughes, D. A., 1 Tach 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

5. Cyhoeddwyd

   Public funding of drugs for orphan diseases

   Hughes, D. & Hughes, D. A., 1 Tach 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

6. Cyhoeddwyd

   Trends and influences on use of antidiabetic drugs in England, 1992-2003.

   Walley, T., Hughes, D. & Kendall, H., 1 Tach 2005, Yn: Pharmacoepidemiology and Drug Safety. 14, 11, t. 769-773

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

   Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   Public funding of drugs for orphan diseases

   Hughes, D. & Hughes, D. A., 1 Gorff 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

9. Cyhoeddwyd

   Empirical analysis of the relationship between dose and duration of drug action

   Hughes, D. & Hughes, D. A., 1 Meh 2005.

   Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

10. Cyhoeddwyd

    Pharmacokinetics, patient compliance and pharmaeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2005.

    Allbwn ymchwil: Cyfraniad at gynhadledd › Papur

11. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid